Omega Therapeutics, Inc.
NASDAQ:OMGA
1.33 (USD) • At close September 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2.134 | 2.36 | 0.989 | 0.831 | 0.759 | 0.516 | 0.735 | 0.595 | 0.476 | 0.268 | 0.144 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.613 | 1.816 | 1.781 | 1.864 | 1.819 | 1.307 | 1.315 | 1.321 | 1.318 | 1.226 | 0.384 | 0.4 | 0.3 | 0.302 | 21.063 | 0 | 0 | 0 |
| Gross Profit
| 1.521 | 0.544 | -0.792 | -1.033 | -1.06 | -0.791 | -0.58 | -0.726 | -0.842 | -0.958 | -0.24 | -0.4 | -0.3 | -0.302 | -21.063 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0.713 | 0.231 | -0.801 | -1.243 | -1.397 | -1.533 | -0.789 | -1.22 | -1.769 | -3.575 | -1.667 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 12.94 | 15.415 | 15.531 | 16.475 | 25.012 | 19.968 | 25.667 | 20.67 | 19.387 | 14.191 | 14.643 | 12.289 | 11.184 | 9.748 | 7.142 | 5.505 | 4.895 | 3.521 |
| General & Administrative Expenses
| 5.774 | 7.396 | 6.156 | 7.869 | 6.206 | 5.954 | 5.355 | 5.198 | 6.202 | 5.406 | 5.692 | 4.459 | 3.637 | 2.745 | 1.814 | 2.047 | 1.01 | 1.365 |
| Selling & Marketing Expenses
| 0.687 | -1.816 | -1.78 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 5.161 | 5.58 | 4.376 | 7.869 | 6.206 | 5.954 | 5.355 | 5.198 | 6.202 | 5.406 | 5.692 | 4.459 | 3.637 | 2.745 | 1.814 | 2.047 | 1.01 | 1.365 |
| Other Expenses
| -0.024 | -0.009 | -0.002 | -0.029 | 0.196 | 0.412 | 0.68 | 0.712 | 0.741 | 0.63 | -0.021 | 0.002 | -0.004 | -0.004 | 0.286 | -0.001 | 0.225 | 0.004 |
| Operating Expenses
| 18.101 | 20.995 | 19.907 | 24.344 | 31.599 | 26.334 | 31.702 | 26.58 | 26.33 | 20.227 | 20.808 | 17.221 | 15.205 | 12.942 | 9.242 | 8.045 | 6.13 | 5.228 |
| Operating Income
| -16.58 | -20.451 | -20.699 | -22.903 | -30.84 | -25.818 | -30.967 | -25.985 | -25.854 | -19.959 | -20.664 | -17.221 | -15.205 | -12.942 | -9.242 | -8.045 | -6.13 | -5.228 |
| Operating Income Ratio
| -7.769 | -8.666 | -20.929 | -27.561 | -40.632 | -50.035 | -42.132 | -43.672 | -54.315 | -74.474 | -143.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0.275 | 0.322 | 0.485 | 0.655 | 0.196 | 0.539 | 0.141 | 0.186 | -0.058 | -0.205 | -0.021 | -0.968 | -0.015 | -0.334 | -0.03 | -0.196 | 0.001 | 0.004 |
| Income Before Tax
| -16.305 | -20.129 | -20.214 | -22.248 | -29.687 | -25.279 | -30.826 | -25.799 | -25.912 | -20.164 | -20.854 | -18.528 | -15.41 | -13.488 | -9.465 | -8.241 | -6.323 | -5.418 |
| Income Before Tax Ratio
| -7.641 | -8.529 | -20.439 | -26.773 | -39.113 | -48.99 | -41.94 | -43.36 | -54.437 | -75.239 | -144.819 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -0 | 1.773 | 4.042 | -1.864 | -0.957 | -1.221 | -0.141 | -0.186 | 0.058 | 0.205 | 0.19 | 1.307 | 0.011 | 0.546 | 0.223 | 0.196 | -0.001 | 0.19 |
| Net Income
| -16.305 | -20.129 | -20.214 | -22.248 | -29.687 | -24.058 | -30.685 | -25.613 | -25.97 | -20.369 | -20.854 | -18.528 | -15.41 | -13.488 | -9.465 | -8.241 | -6.323 | -5.418 |
| Net Income Ratio
| -7.641 | -8.529 | -20.439 | -26.773 | -39.113 | -46.624 | -41.748 | -43.047 | -54.559 | -76.004 | -144.819 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.3 | -0.36 | -0.37 | -0.4 | -0.54 | -0.48 | -0.64 | -0.54 | -0.54 | -0.43 | -0.44 | -0.57 | -0.33 | -0.43 | -0.3 | -0.26 | -0.2 | -0.17 |
| EPS Diluted
| -0.3 | -0.36 | -0.37 | -0.4 | -0.54 | -0.48 | -0.64 | -0.54 | -0.54 | -0.43 | -0.44 | -0.57 | -0.33 | -0.43 | -0.3 | -0.26 | -0.2 | -0.17 |
| EBITDA
| -15.967 | -18.635 | -18.918 | -22.903 | -29.021 | -25.818 | -30.967 | -25.591 | -25.447 | -19.633 | -20.301 | -16.855 | -14.872 | -12.644 | -8.841 | -7.772 | -5.905 | -5.012 |
| EBITDA Ratio
| -7.482 | -7.896 | -19.128 | -27.561 | -38.236 | -50.035 | -42.132 | -43.01 | -53.46 | -73.257 | -140.979 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |